menu 1
menu 2
menu 3
menu 4
menu 5
menu 6
menu 7

The AdnaTest ColonCancer and AdnaTest BreastCancer products are CE-certified for the detection of circulating tumor cells.

For odering of the following products please click here to find your appropriate distributor.

Important note for US customers: In USA, AdnaTest BreastCancer and AdnaTest ColonCancer are not yet approved by the FDA and must not be used for diagnostic purposes; these kits are for research use only. AdnaGen disclaims all liabilities for any diagnostic application.
Name
Size
Art. No.
    
Manual
AdnaTest ColonCancerSelect
12 selections
T-1-504
    
AdnaTest ColonCancerDetect
12 detections
T-1-505
    
AdnaTest BreastCancerSelect
12 selections
T-1-508
    
AdnaTest BreastCancerDetect
12 detections
T-1-509
    
AdnaTest ProstateCancerSelect
12 selections
T-1-520
    
AdnaTest ProstateCancerDetect
12 detections
T-1-521
    
AdnaTest
ER/PR-Detect
12 detections
T-1-532
  
AdnaTest
EMT-1/Stem Cell
Select + Detect
12 selections
T-1-533
Select
 
 
Detect
 
 
AdnaCollect
12 systems
T-1-600
   
AdnaMag-L
1 magnet stand
T-1-700
   

 

Product description
AdnaTest CancerSelect
In the first step cancer cells will be enriched in vitro from cancer patients` blood samples (EDTA or AdnaCollect) using magnetic bead conjugated antibodies. The antibody cocktail was carefully optimized for the cancer type.

AdnaTest CancerDetect
The isolated mRNA is transcribed into cDNA, that can be amplified in a following multiplex-PCR. The multiplex PCR detection step analyses the tumor associated gene expression of a variety of relevant tumor markers to make sure that the selected cells are cancer cells. Tests are offered as reagent sets for the detection of breast and colon cancer cells in human blood.

The advantages of AdnaGen's test
The combination of a variety of selection markers (antibodies) and a set of molecular tumor markers (mRNAs) takes care of the heterogeneity of the cancer cells` gene expression preventing false negative and false positive results due to either illegitimate transcription in normal cells or individual changes in gene expression in general and during chemotherapy.